Multivessel coronary thrombosis treated with abciximab (ReoPro) in a patient with essential thrombocythemia

Clin Cardiol. 1998 Feb;21(2):134-8. doi: 10.1002/clc.4960210218.


A 50-year-old man was admitted with acute inferior and anterior myocardial infarction. The patient was diagnosed with essential thrombocythemia (ET) based on the findings of marked thrombocytosis of 1,113 x 10(3)/mm3, splenomegaly, and numerous clumping megakaryocytes on bone marrow biopsy. Emergent coronary angiography revealed extensive multivessel thrombosis involving the left main coronary artery and completely occluding the proximal right coronary artery. In addition to standard therapy with aspirin, heparin, and primary angioplasty of the right coronary artery, the patient received additional antiplatelet therapy with ticlopidine, hydroxyurea, and the platelet glycoprotein IIb/IIIa receptor-inhibiting monoclonal antibody drug abciximab (ReoPro). Serial coronary angiograms 1 and 5 days following the infarction showed progressive thrombus resolution. The pathophysiologic mechanisms and therapeutic challenges of ET-associated coronary thrombosis are discussed in this report.

Publication types

  • Case Reports

MeSH terms

  • Abciximab
  • Angioplasty
  • Antibodies, Monoclonal / therapeutic use*
  • Biopsy
  • Bone Marrow / pathology
  • Coronary Angiography
  • Coronary Thrombosis / complications
  • Coronary Thrombosis / diagnostic imaging
  • Coronary Thrombosis / drug therapy*
  • Electrocardiography
  • Follow-Up Studies
  • Humans
  • Immunoglobulin Fab Fragments / therapeutic use*
  • Male
  • Middle Aged
  • Myocardial Infarction / diagnostic imaging
  • Myocardial Infarction / etiology
  • Myocardial Infarction / therapy
  • Platelet Aggregation Inhibitors / therapeutic use*
  • Platelet Count
  • Thrombocythemia, Essential / complications*


  • Antibodies, Monoclonal
  • Immunoglobulin Fab Fragments
  • Platelet Aggregation Inhibitors
  • Abciximab